Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IBRX NASDAQ:KYMR NASDAQ:NRIX NASDAQ:NUVL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBRXImmunityBio$8.22-7.3%$7.84$1.95▼$12.43$9.29B0.0112.38 million shs12.81 million shsKYMRKymera Therapeutics$119.35+0.3%$90.61$36.65▼$130.05$9.79B1.951.26 million shs665,608 shsNRIXNurix Therapeutics$23.06-6.6%$18.44$8.19▼$25.08$2.55B1.82.29 million shs1.55 million shsNUVLNuvalent$123.90+0.1%$111.72$71.13▼$123.91$9.78B1.142.18 million shs2.06 million shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBRXImmunityBio-7.33%-12.92%+17.77%+12.91%+194.62%KYMRKymera Therapeutics+0.29%+5.14%+52.56%+40.33%+164.17%NRIXNurix Therapeutics-6.60%-3.84%+50.72%+43.86%+74.96%NUVLNuvalent+0.06%+0.14%+0.45%+20.60%+52.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBRXImmunityBio$8.22-7.3%$7.84$1.95▼$12.43$9.29B0.0112.38 million shs12.81 million shsKYMRKymera Therapeutics$119.35+0.3%$90.61$36.65▼$130.05$9.79B1.951.26 million shs665,608 shsNRIXNurix Therapeutics$23.06-6.6%$18.44$8.19▼$25.08$2.55B1.82.29 million shs1.55 million shsNUVLNuvalent$123.90+0.1%$111.72$71.13▼$123.91$9.78B1.142.18 million shs2.06 million shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBRXImmunityBio-7.33%-12.92%+17.77%+12.91%+194.62%KYMRKymera Therapeutics+0.29%+5.14%+52.56%+40.33%+164.17%NRIXNurix Therapeutics-6.60%-3.84%+50.72%+43.86%+74.96%NUVLNuvalent+0.06%+0.14%+0.45%+20.60%+52.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBRXImmunityBio 2.71Moderate Buy$14.2072.75% UpsideKYMRKymera Therapeutics 2.96Moderate Buy$121.411.73% UpsideNRIXNurix Therapeutics 2.79Moderate Buy$33.7746.44% UpsideNUVLNuvalent 2.15Hold$127.733.09% UpsideCurrent Analyst Ratings BreakdownLatest NRIX, IBRX, NUVL, and KYMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2026NRIXNurix Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $34.007/10/2026NRIXNurix Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $34.007/10/2026NRIXNurix Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$34.00 ➝ $40.007/10/2026NRIXNurix Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$30.00 ➝ $33.007/10/2026NRIXNurix Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.007/10/2026NRIXNurix Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.006/30/2026KYMRKymera Therapeutics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$110.00 ➝ $125.006/29/2026KYMRKymera Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$117.00 ➝ $155.006/29/2026KYMRKymera Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$116.00 ➝ $136.006/29/2026NRIXNurix Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$28.006/26/2026KYMRKymera Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$106.00 ➝ $129.00(Data available from 7/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBRXImmunityBio$113.29M75.99N/AN/A($0.51) per share-16.12KYMRKymera Therapeutics$39.21M250.39N/AN/A$19.42 per share6.15NRIXNurix Therapeutics$83.98M28.40N/AN/A$5.29 per share4.36NUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBRXImmunityBio-$351.40M-$0.85N/AN/AN/A-606.15%N/A-59.53%8/4/2026 (Estimated)KYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%8/10/2026 (Estimated)NRIXNurix Therapeutics-$264.46M-$3.16N/AN/AN/A-928.44%-73.57%-55.45%N/ANUVLNuvalent-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%8/6/2026 (Estimated)Latest NRIX, IBRX, NUVL, and KYMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026NUVLNuvalent-$1.44N/AN/AN/A$0.25 millionN/A8/4/2026Q2 2026IBRXImmunityBio-$0.09N/AN/AN/A$49.20 millionN/A7/9/2026Q2 2026NRIXNurix Therapeutics-$0.72-$0.81-$0.09-$0.81$15.29 million$9.04 million5/7/2026Q1 2026IBRXImmunityBio-$0.08-$0.62-$0.54-$0.62$43.07 million$44.21 million5/7/2026Q1 2026NUVLNuvalent-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIBRXImmunityBioN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBRXImmunityBioN/A6.676.66KYMRKymera TherapeuticsN/A10.8110.81NRIXNurix TherapeuticsN/A6.016.01NUVLNuvalentN/A16.1416.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBRXImmunityBio8.58%KYMRKymera TherapeuticsN/ANRIXNurix TherapeuticsN/ANUVLNuvalent97.26%Insider OwnershipCompanyInsider OwnershipIBRXImmunityBio66.10%KYMRKymera Therapeutics15.98%NRIXNurix Therapeutics6.70%NUVLNuvalent5.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIBRXImmunityBio5901.05 billion355.05 millionOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionableNRIXNurix Therapeutics300103.41 million96.48 millionOptionableNUVLNuvalent4079.00 million75.03 millionOptionableNRIX, IBRX, NUVL, and KYMR HeadlinesRecent News About These CompaniesInsider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 2,111 Shares of StockJuly 10 at 5:06 PM | marketbeat.comNuvalent (NASDAQ:NUVL) CEO Sells 30,000 Shares of StockJuly 9 at 6:21 AM | insidertrades.comBiotech rally rests on fundamentals, M&A appetite, says ROTY's FaisonJuly 9 at 5:30 AM | msn.comAlexandra Balcom Sells 11,430 Shares of Nuvalent (NASDAQ:NUVL) StockJuly 7, 2026 | insidertrades.comShareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public ShareholdersJuly 2, 2026 | globenewswire.comNuvalent, Inc. (NASDAQ:NUVL) Short Interest UpdateJuly 1, 2026 | marketbeat.comBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN), SUNation Energy, Inc. (Nasdaq – SUNE), Taylor Morrison Home Corporation (NYSE - TMHC),June 30, 2026 | globenewswire.comBernstein Sticks to Its Buy Rating for Nuvalent (NUVL)June 25, 2026 | theglobeandmail.comNuvalent, Inc. $NUVL Position Lifted by Perceptive Advisors LLCJune 18, 2026 | marketbeat.comPolar Capital Holdings Plc Boosts Position in Nuvalent, Inc. $NUVLJune 17, 2026 | marketbeat.comNUVL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Nuvalent to GSKJune 16, 2026 | globenewswire.comNicholas Investment Partners LP Boosts Holdings in Nuvalent, Inc. $NUVLJune 14, 2026 | marketbeat.comFirst Turn Management LLC Has $37.09 Million Stock Holdings in Nuvalent, Inc. $NUVLJune 14, 2026 | marketbeat.comMarketBeat Week in Review – 06/08 - 06/12 (NUVL)...June 13, 2026 | marketbeat.comRhenman & Partners Asset Management AB Acquires 110,850 Shares of Nuvalent, Inc. $NUVLJune 13, 2026 | marketbeat.comGuggenheim downgrades Nuvalent (NUVL) to a HoldJune 12, 2026 | theglobeandmail.comNuvalent (NUVL) was downgraded to a Hold Rating at TD CowenJune 12, 2026 | theglobeandmail.comNuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective Tyrosine Kinase InhibitorsJune 11, 2026 | seekingalpha.comPatent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion...June 11, 2026 | marketbeat.comNuvalent (NASDAQ:NUVL) Downgraded by Truist Financial to HoldJune 11, 2026 | marketbeat.comNuvalent (NASDAQ:NUVL) Upgraded to Hold at GuggenheimJune 11, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 2026Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 BillionBy Jeffrey Neal Johnson | June 11, 2026NRIX, IBRX, NUVL, and KYMR Company DescriptionsImmunityBio NASDAQ:IBRX$8.22 -0.65 (-7.33%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$8.23 +0.01 (+0.11%) As of 07/10/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Kymera Therapeutics NASDAQ:KYMR$119.35 +0.35 (+0.29%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$116.02 -3.32 (-2.79%) As of 07/10/2026 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Nurix Therapeutics NASDAQ:NRIX$23.06 -1.63 (-6.60%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$23.01 -0.05 (-0.22%) As of 07/10/2026 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Nuvalent NASDAQ:NUVL$123.90 +0.07 (+0.06%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$123.95 +0.05 (+0.04%) As of 07/10/2026 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab’s Stock Drop Comes With a Bullish Twist Micron's $250 Billion Bet Could Reshape the AI Memory Race AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target IQM's Nasdaq Debut Could Change the Quantum Race for D-Wave PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth PepsiCo’s Dividend Could Turn Patience Into Real Profit Lockheed Martin Secures the Ultimate Defense Moat Why Levi's Digital Strategy Is Paying Off in a Big Way Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
